甲磺酸伊马替尼联合VDLD方案诱导治疗儿童急性淋巴细胞白血病的临床疗效
Clinical efficacy of imatinib mesylate combined with VDLD regimen in the induction treatment of acute lymphoblastic leukemia in children
吴爱月 1向金峰 2周柳3
作者信息
- 1. 南阳市中心医院儿科,河南 南阳 473000
- 2. 南阳市中心医院儿童血液内科,河南 南阳 473000
- 3. 南阳市中心医院放射治疗科,河南 南阳 473000
- 折叠
摘要
目的 探讨甲磺酸伊马替尼联合长春地辛+地塞米松+培门冬酶+去甲氧柔红霉素(VDLD)方案诱导治疗儿童急性淋巴细胞白血病的临床疗效.方法 根据化疗方案的不同将104例急性淋巴细胞白血病患儿分为对照组(n=52)和观察组(n=52),对照组患儿给予VDLD方案治疗,观察组患儿给予甲磺酸伊马替尼联合VDLD方案治疗.比较两组患儿的临床疗效、肿瘤标志物[血管内皮细胞生长因子(VEGF)、血管内皮细胞生长因子受体(VEGFR)、碱性成纤维细胞生长因子(bFGF)]水平、不良反应发生情况及预后情况.结果 观察组患儿的治疗总有效率和5年生存率均高于对照组,5年复发率低于对照组,差异均有统计学意义(P﹤0.05).治疗后,两组患儿VEGF、VEFGR、bFGF水平均低于本组治疗前,观察组患儿VEGF、VEFGR、bFGF水平均低于对照组,差异均有统计学意义(P﹤0.05).两组患儿的不良反应总发生率比较,差异无统计学意义(P﹥0.05).结论 甲磺酸伊马替尼联合VDLD方案诱导治疗儿童急性淋巴细胞白血病,能够提高临床疗效,降低复发率,且不会增加不良反应,安全性较高.
Abstract
Objective To investigate the clinical efficacy of imatinib mesylate combined with vindesine+dexametha-sone+peraspartase+demethoxydaunorubicin(VDLD)regimen in the induction treatment of acute lymphoblastic leuke-mia in children.Method A total of 104 children with acute lymphoblastic leukemia were divided into control group(n=52)and observation group(n=52)according to different chemotherapy regimens.The control group was treated with VDLD regimen,and the observation group was treated with imatinib mesylate combined with VDLD regimen.The clini-cal efficacy,tumor markers[vascular endothelial growth factor(VEGF),vascular endothelial growth factor receptor(VEGFR),basic fibroblast growth factor(bFGF)]levels,incidence of adverse reactions and prognosis of the two groups were compared.Result The total effective rate and 5-year survival rate in observation group were higher than those in control group,and 5-year recurrence rate was lower than that in control group,and the differences were statistically signif-icant(P<0.05).After treatment,the levels of VEGF,VEFGR and bFGF in two groups were lower than those before treat-ment,and the levels of VEGF,VEFGR and bFGF in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse re-actions between the two groups(P>0.05).Conclusion The combination of imatinib mesylate and VDLD regimen in the induction treatment of acute lymphoblastic leukemia in children can improve the clinical efficacy,reduce the recurrence rate,and without increasing adverse reactions,with high safety.
关键词
急性淋巴细胞白血病/甲磺酸伊马替尼/VDLD方案/不良反应Key words
acute lymphoblastic leukemia/imatinib mesylate/VDLD regimen/adverse reaction引用本文复制引用
基金项目
河南省医学科技攻关计划联合共建项目(LHGJ20210980)
出版年
2024
NETL
NSTL
万方数据